RTP Mobile Logo
Thyroid Cancer Update, Issue 1, 2013
Released October 2013

Featuring interviews with Drs Steven I Sherman and Marcia S Brose. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Thyroid carcinoma, one of the 10 most common types of cancer in the United States, has doubled in incidence during the past decade. In 2013 approximately 60,220 new cases will be diagnosed, with more than 1,800 deaths. This heterogeneous disease — comprising differentiated, medullary and anaplastic thyroid carcinoma — has historically been the purview of endocrinologists. Most patients will be cured with local treatments and radioactive iodine. Medical oncology intervention typically only occurs for those patients with progressive metastatic disease. Only 2 new agents have been approved for the treatment of this disease in the past 15 years — cabozantinib and vandetanib — although several tyrosine kinase inhibitors (TKIs) (eg, sorafenib) have been investigated and used in the treatment of advanced disease and ongoing research is evaluating the role of other targeted treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Thyroid Cancer Update uses one-on-one conversations with leading oncology investigators discussing the interdisciplinary management of this prevalent malignancy. By providing access to the latest research developments and expert perspectives on the disease, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Identify the role of tumor markers in the management of different histologic subtypes of thyroid carcinoma.
    • Use currently available data sets to guide the rational integration of TKIs into the treatment of unresectable, locally advanced and metastatic thyroid carcinoma.
    • Formulate strategies to mitigate TKI-related side effects to maintain patients on active therapy while minimizing its impact on quality of life.
    • Develop an understanding of emerging efficacy and side-effect data with novel agents (eg, mTOR inhibitors, BRAF inhibitors) under evaluation for thyroid cancer.
    • Counsel appropriately selected patients with thyroid cancer about the availability of ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr ShermanConsulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Lilly, Novo Nordisk A/S, Veracyte Inc; Contracted Research: Genzyme Corporation, Pfizer Inc. Dr BroseAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Onyx Pharmaceuticals Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, GlaxoSmithKline, Onyx Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc and Exelixis Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2013
    Expiration date: October 2014

Acknowledge and close

Listen to audio:
Thyroid Cancer Update, Issue 1, 2013
Released October 2013

Featuring interviews with Drs Steven I Sherman and Marcia S Brose. (Audio Content)

Read print: